Every letter we have printed

Species differences in the receptor itself are large enough that preclinical potency does not transfer cleanly, and the transfer is usually asserted rather than demonstrated. It is worth checking which species a quoted figure came from.

Where two activities act on the same downstream endpoint, additivity cannot be assumed and is rarely tested. The interaction term is the interesting quantity and almost no study is designed to estimate it.

A caution on cross-molecule potency comparisons. Milligram-for-milligram statements between agents with different receptor profiles and different half-lives are close to meaningless, and they are the commonest error I see in general coverage. Your department avoids them, which is why I read it.

Body-size scaling is assumed in this discussion and was not built into the studied schedules, which are fixed rather than weight-based. Whether that is a finding or a convenience is not resolved anywhere in the literature.

One more argument against reasoning past the ceiling: the exposure achieved depends on the material as well as the dose, and where peptide content is undocumented the dose is nominal. Arithmetic performed on an uncertain quantity is not made more precise by making the quantity larger.

I had a nine-week gap last year because my supplier stopped answering messages. Nobody in any clinical setting I dealt with treated that as a pharmacological event. Your framing of supply interruption as a dosing decision is the first time I have seen it written down.

The energetics of a smaller body are sufficient on their own to produce a decelerating curve, and that explanation is rarely offered alongside the pharmacological ones. It is the null hypothesis and it is not being tested against.

A modest defence of the percentage. It is the only figure in this trade that is generated by an instrument rather than asserted by a seller, and for all its limits that is not nothing. I would rather argue about what a number means than have no number to argue about.

I run a small teaching laboratory and I use this department as reading for second-year students. The point that lands hardest with them is that four defensible analytical choices can move a reported figure by nearly two points without anyone behaving badly. They arrive believing measurement is a fact and leave understanding it is a procedure.

Your article argues for two orthogonal methods and reports the lower figure, but the people running a single twelve-minute method have a cost story you do not address. A full orthogonal pair doubles the turnaround and at least doubles the cost, which is why the market does not do it. The criticism of method disclosure is fair. The criticism that a single method is wrong is unfair to the constraints people operate under.

Reasons given publicly are shaped by what the audience will accept, and cost in particular is under-reported for that reason. A private survey and a public forum will not agree, and the gap between them is itself a finding.

Reasons are ranked in most reporting and the ranking is a function of the category list. Change the list and the ranking changes, which means the headline finding of most of these surveys is a property of their questionnaire.

Reasons interact. Cost that would be tolerable alone becomes decisive alongside a tolerability issue that would also have been tolerable alone. Single-reason coding cannot represent this and almost all coding is single-reason.

The reason I have most often encountered is a simple one and appears in no list: it was always meant to be temporary. Somebody who set out to stop and then stopped has not discontinued in any interesting sense, and they are counted alongside those who did.

Hydration state, recent exercise and time of day all move these estimates, and serial scans done under different conditions are not comparable. Standardising the conditions is free and it is the single largest improvement available to anybody tracking themselves.

Bioimpedance estimates total body water and infers the rest, which means that during rapid change it is estimating the quantity that is moving fastest and is least stable. Its precision is fine and its accuracy is a different matter, and the two get conflated constantly.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

Where a trial protocol offered activity advice rather than a programme, the coverage reports it as a training intervention. Advice and supervision are different interventions with different effect sizes.

Where an approach requires a clinician, saying so plainly is the most useful sentence in the piece. A great deal of published guidance in this area assumes access that many readers do not have, and pretending otherwise helps nobody.

Where a trial protocol specified a management approach, that fact belongs in any discussion of the trial’s tolerability results, because the results describe a managed population. It is usually in the methods and never in the summary.

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Where an event is described in the literature as rare, it would help enormously to print the actual figure rather than the adjective. Rare means different things in a regulatory glossary and in ordinary speech, and both audiences read the same sentence.

The tone is the achievement. Serious without being solemn, and sceptical without the sneer that usually accompanies it in coverage of this subject.

Lipohypertrophy is the outcome rotation actually prevents, and it develops over months of repeated use of one small area. It is a slow, quiet problem, and by the time it is visible it has been forming for a long time.

The published work on this comes from long-established clinical practice in other therapeutic areas and transfers reasonably well. Citing the source would raise the standard of the discussion considerably.

Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?

Where custody is genuinely maintained, the cost is not in the paperwork but in the handling: dedicated packaging, tracked transfer, a named recipient at each end. It is perfectly achievable and it roughly doubles the price of a determination.

Photographs are a poor substitute for a signature and a good substitute for nothing. Vial, label, seal, packaging, with a timestamp — five minutes of work that has settled every dispute I have been involved in.

Where a badge does link to a report, the report is often a scan of a printout. The information is there and the format announces that nobody expected it to be read. Presentation is a signal about intended audience.

The comparison with food-hygiene ratings is instructive. Those are dated, they are issued by a body with no commercial relationship to the premises, and they can go down. Three properties, none of which this market’s marks possess, and each of which could be adopted independently.

Comparing across programmes is impossible at present because none of them describes its purchasing protocol in enough detail to reproduce. Publishing the protocol matters more than publishing another result.

Sample size defeats most of what is published. A single blind purchase from one supplier tells you about one vial. It is worth having and it is not a characterisation of anything, and the gap between those two statements is where most confusion in this market lives.

I would like to know how often a blind programme has been unable to complete a purchase — order cancelled, payment refused, nothing delivered. Those are results, they are never published, and they may be the most informative data any programme collects.

The reference population for most intervals is a convenience sample of donors or staff, and its age and sex composition is rarely printed with the interval. Where it is, it is often not the population reading the result.

Time of day matters for several of the analytes discussed in this context, and a series collected at different hours is a series with a systematic wobble in it. Same laboratory, same time, same conditions is worth more than any additional test.

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

Frequency deserves a word. Repeating a panel monthly during a period of change produces a series in which most movement is variation rather than trend, and reading each report as news is a recipe for chasing noise.

Emptying rate and symptom intensity correlate poorly at the individual level, which is one of the more interesting findings in the area. It means the mechanism is necessary and not sufficient, and coverage that treats them as the same thing is misleading.

The vagal afferent pathway is the part of the story with the strongest experimental support and the weakest presence in general discussion, presumably because it is harder to draw. Mechanistic coverage tends to follow what can be diagrammed.